+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Global Forecast 2026-2032- Product Image
Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968573
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Paroxysmal Nocturnal Hemoglobinuria Treatment Market is projected to reach USD 5.88 Billion in 2026. It is expected to continue growing at a CAGR of 9.34%, reaching USD 10.07 Billion by 2032.

Paroxysmal nocturnal hemoglobinuria treatment has moved from supportive care to precision complement inhibition, reshaping outcomes for patients with this rare, acquired hematopoietic stem cell disorder. PNH is characterized by complement-mediated hemolysis, anemia, thrombosis risk, fatigue, kidney complications, and impaired quality of life, with diagnosis typically confirmed by high-sensitivity flow cytometry detecting glycosylphosphatidylinositol-anchored protein deficiencies on blood cells.

The treatment landscape is anchored by proven complement therapies, including C5 inhibitors such as eculizumab and ravulizumab, proximal complement inhibitors such as pegcetacoplan, oral factor B inhibition with iptacopan, and add-on factor D inhibition with danicopan for clinically significant extravascular hemolysis in patients receiving C5 blockade. These advances are expanding the competitive focus from hemolysis control alone to hemoglobin normalization, transfusion avoidance, dosing convenience, breakthrough hemolysis prevention, patient adherence, and long-term safety.

Transformative Shifts in the PNH Treatment Landscape

The most important shift in paroxysmal nocturnal hemoglobinuria treatment is the transition from terminal complement blockade as the dominant standard to a broader portfolio that targets both terminal and proximal complement pathways. C5 inhibition remains clinically established for reducing intravascular hemolysis and thrombotic risk, while C3, factor B, and factor D approaches address residual disease activity, including anemia driven by extravascular hemolysis in selected patients.

Competition is also shifting around route of administration and treatment burden. Long-acting intravenous dosing, self-administered subcutaneous options, and oral therapies are redefining patient preference, clinic capacity, payer evaluation, and real-world adherence. As more agents gain regulatory acceptance, stakeholders must differentiate on durable lactate dehydrogenase control, hemoglobin improvement, transfusion independence, safety monitoring, vaccination requirements, and evidence in treatment-naive versus previously treated populations.

Cumulative Impact of Artificial Intelligence on PNH Care

Artificial intelligence is beginning to influence the PNH treatment ecosystem by improving rare disease identification, clinical trial matching, laboratory analytics, and post-market surveillance. Because PNH symptoms overlap with aplastic anemia, myelodysplastic syndromes, autoimmune hemolysis, and unexplained thrombosis, AI-enabled screening of electronic health records can help flag patients with patterns such as persistent hemolysis, cytopenias, elevated lactate dehydrogenase, thrombosis history, and transfusion dependence for specialist review.

The cumulative impact of AI is expected to be strongest where data quality is high and clinical validation is rigorous. Machine learning can support flow cytometry quality control, predict breakthrough hemolysis risk, identify adherence gaps, optimize site selection for rare disease trials, and strengthen pharmacovigilance by detecting safety signals across registries, claims, and spontaneous reporting systems. However, AI should be deployed as decision support rather than autonomous diagnosis, with transparent algorithms, bias testing, clinician oversight, and compliance with health data privacy regulations.

Key Regional Insights: North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa

North America remains a leading region for paroxysmal nocturnal hemoglobinuria treatment because of early regulatory adoption, high specialist density, established reimbursement pathways, and strong participation in rare disease clinical trials. The United States has been a major launch market for complement inhibitors, while Canada’s access environment is shaped by health technology assessment, provincial reimbursement decisions, and evidence requirements for high-cost medicines.

Europe benefits from centralized European Medicines Agency review, national reimbursement systems, and mature hematology networks across major markets. The European Union’s rare disease policy framework and orphan drug incentives support innovation, but country-level pricing negotiations can create staggered access. The United Kingdom, Germany, France, Italy, and Spain remain important markets due to advanced diagnostic capacity, specialist care pathways, and structured assessment of clinical value, safety, and budget impact.

Asia-Pacific is gaining strategic importance as Japan, China, South Korea, Australia, and India expand rare disease awareness, diagnostic infrastructure, and access to advanced biologics and oral therapies. Latin America shows growing need but uneven access, with Brazil and Mexico representing key markets where reimbursement, affordability, and tertiary-center capacity influence adoption. The Middle East, led by Gulf health systems, is investing in specialty care, rare disease programs, and advanced hospital infrastructure, while Africa faces the largest gaps in diagnosis, reimbursement, laboratory capacity, and availability of complement-targeted therapies.

Key Group Insights: G7, EU, BRICS, ASEAN, GCC, and NATO

The G7 countries collectively represent the most commercially mature environment for PNH treatment, supported by advanced regulatory agencies, established rare disease frameworks, broad hematology expertise, and stronger ability to fund high-cost biologics and innovative oral therapies. Within the G7, market access still differs by payer model, with the United States emphasizing commercial and public coverage dynamics and European members relying on national value assessments and negotiated pricing.

The European Union is central to the treatment landscape because centralized marketing authorization can support multi-country entry, while reimbursement remains nationally determined. BRICS countries offer long-term growth potential due to large populations and expanding specialty care, but PNH diagnosis rates and access to complement inhibitors vary significantly across Brazil, Russia, India, China, and South Africa. ASEAN markets are increasingly relevant as tertiary hospitals improve hematology capabilities, although affordability, laboratory access, and reimbursement remain key barriers to wider adoption.

GCC countries are important for premium specialty medicine adoption because several health systems prioritize advanced hospital infrastructure, rare disease programs, and international treatment standards. NATO membership is not a healthcare market structure, but many NATO countries overlap with high-income North American and European systems where regulatory alignment, resilient supply chains, cross-border clinical collaboration, and public health security considerations can influence biologics availability.

Key Country Insights Across Major PNH Treatment Markets

The United States is the primary innovation and commercialization hub for PNH treatment, supported by FDA orphan drug pathways, leading academic hematology centers, and rapid adoption of approved complement inhibitors. Canada follows a more centralized evidence review and provincial reimbursement model. Mexico and Brazil show rising demand for rare disease care, but treatment access often depends on public-sector coverage, litigation pathways, private insurance, and specialist-center availability.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have strong diagnostic and treatment infrastructure, although pricing, reimbursement, and prescribing criteria differ. Germany often provides earlier post-authorization access within its reimbursement framework, while France, Italy, Spain, and the United Kingdom rely on structured health technology assessment and budget impact review. Russia has specialist expertise in major cities, but access can be constrained by procurement, reimbursement variability, and regional differences in specialty care delivery.

China is expanding rare disease policy support and domestic innovation capacity, making it a major long-term growth market. Japan has a mature rare disease reimbursement environment and high clinical adoption of approved therapies. South Korea and Australia maintain advanced hematology care and regulatory systems aligned with evidence-based access. India has significant unmet need because of large population scale, underdiagnosis, affordability constraints, and uneven access to high-cost complement inhibitors.

Actionable Recommendations for PNH Treatment Leaders

Industry leaders should prioritize differentiated evidence that reflects how hematologists and payers evaluate modern PNH treatment: sustained hemolysis control, hemoglobin improvement, transfusion independence, reduction in breakthrough hemolysis, patient-reported fatigue improvement, safety, and adherence. Head-to-head and real-world evidence will become increasingly important as multiple therapies compete across C5, C3, factor B, and factor D mechanisms.

Organizations should also invest in diagnosis acceleration, including physician education, laboratory partnerships, and AI-enabled case-finding tools that route suspected patients to confirmatory flow cytometry. Market access teams need country-specific value dossiers that address rare disease budget impact, long-term outcomes, vaccination and infection risk management, administration costs, and quality-of-life gains. Patient support programs should be designed around adherence, home administration training, oral therapy persistence, and rapid management of breakthrough symptoms.

Research Methodology for Verified PNH Treatment Insights

This executive summary is based on a structured secondary research methodology using verified sources such as regulatory approvals and prescribing information from recognized medicines agencies, peer-reviewed hematology literature, clinical guideline statements, clinical trial publications, rare disease registries, and health technology assessment materials. The analysis emphasizes validated clinical and regulatory facts rather than unsubstantiated market estimates.

The research approach included therapy landscape mapping by mechanism of action, review of regional access conditions, assessment of reimbursement and policy environments, evaluation of innovation trends, and synthesis of evidence on unmet needs in PNH care. Insights were triangulated across regulatory, clinical, payer, and real-world evidence sources to support an SEO-ready market perspective for stakeholders in pharmaceutical strategy, diagnostics, commercialization, and healthcare investment.

Conclusion: The Future of PNH Treatment

The paroxysmal nocturnal hemoglobinuria treatment landscape is entering a more competitive and patient-centered phase. Established C5 inhibitors continue to play a central role, while proximal complement inhibitors and oral therapies are expanding the definition of optimal disease control. The landscape is increasingly shaped by convenience, durability, residual anemia management, real-world outcomes, and payer confidence in long-term value.

Future leadership will depend on evidence generation, earlier diagnosis, equitable access, and safe integration of digital and AI-enabled tools. Stakeholders that align clinical differentiation with regional reimbursement realities, robust safety management, and patient needs will be best positioned to advance outcomes in this high-value rare disease treatment landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Treatment Class
7.1. Introduction
7.2. Complement Inhibitors
7.2.1. Eculizumab
7.2.2. Ravulizumab
7.3. Therapy
7.4. Supportive & Preventive Care
7.4.1. Blood Transfusion
7.4.2. Iron Chelation Therapy
7.4.3. Anticoagulation
7.4.4. Iron & Folic Acid Supplementation
8. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Route of Administration
8.1. Introduction
8.2. Intravenous
8.3. Subcutaneous
8.4. Oral Administration
9. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Line of Therapy
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line
10. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Dosing Pattern
10.1. Introduction
10.2. Standard Interval Parenteral
10.3. Extended Interval Parenteral
10.4. Daily Oral Maintenance
11. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by End Use
11.1. Introduction
11.2. Hospitals
11.3. Specialty Clinics / Hematology Centers
11.4. Homecare Settings
12. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Europe
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Country
15.1. United States
15.2. China
15.3. Canada
15.4. Japan
15.5. Germany
15.6. India
15.7. Brazil
15.8. Mexico
15.9. United Kingdom
15.10. France
15.11. Australia
15.12. Italy
15.13. South Korea
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AstraZeneca PLC
17.2. Alnylam Pharmaceuticals, Inc.
17.3. Samsung Bioepis Co., Ltd.
17.4. Novo Nordisk A/S
17.5. Apellis Pharmaceuticals, Inc.
17.6. Novartis AG
17.7. F. Hoffmann-La Roche Ltd.
17.8. Regeneron Pharmaceuticals, Inc.
17.9. Chugai Pharmaceutical Co., Ltd.
17.10. Akari Therapeutics, Plc
17.11. Amgen Inc.
17.12. BioCryst Pharmaceuticals, Inc.
17.13. Kira Pharmaceuticals, Inc.
17.14. NovelMed Therapeutics, Inc.
17.15. Sanofi S.A.
17.16. Swedish Orphan Biovitrum AB
List of Figures
FIGURE 1. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ECULIZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ECULIZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ECULIZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL RAVULIZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL RAVULIZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL RAVULIZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL SUPPORTIVE & PREVENTIVE CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL SUPPORTIVE & PREVENTIVE CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL SUPPORTIVE & PREVENTIVE CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL BLOOD TRANSFUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL BLOOD TRANSFUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL BLOOD TRANSFUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL IRON CHELATION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL IRON CHELATION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL IRON CHELATION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ANTICOAGULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ANTICOAGULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ANTICOAGULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL IRON & FOLIC ACID SUPPLEMENTATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL IRON & FOLIC ACID SUPPLEMENTATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL IRON & FOLIC ACID SUPPLEMENTATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL THIRD LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL THIRD LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL THIRD LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL STANDARD INTERVAL PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL STANDARD INTERVAL PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL STANDARD INTERVAL PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL EXTENDED INTERVAL PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL EXTENDED INTERVAL PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL EXTENDED INTERVAL PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL DAILY ORAL MAINTENANCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL DAILY ORAL MAINTENANCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL DAILY ORAL MAINTENANCE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SPECIALTY CLINICS / HEMATOLOGY CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SPECIALTY CLINICS / HEMATOLOGY CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SPECIALTY CLINICS / HEMATOLOGY CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 88. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 93. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 97. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 99. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 100. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 101. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 102. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 103. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 104. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 105. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 115. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 117. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 118. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 119. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 120. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 121. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 122. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 123. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 127. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 136. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 137. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 138. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 139. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 140. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 141. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 142. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 143. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 145. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 146. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 147. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 148. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 149. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 150. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 151. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 152. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 154. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 155. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 156. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 157. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 158. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 159. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 160. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 170. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 172. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 173. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 174. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 175. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 176. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 177. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 178. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 179. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 181. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 182. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 183. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 184. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 185. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 186. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 187. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 188. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 189. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 190. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 191. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 192. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 193. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 194. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 195. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 196. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 197. UNITED STATES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 198. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 199. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 200. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 201. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 202. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 203. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 204. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 205. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 206. CHINA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 207. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 208. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 209. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 210. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 211. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 212. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 213. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 214. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 215. CANADA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 216. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 217. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 218. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 219. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 220. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 221. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 222. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 223. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 224. JAPAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 225. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 227. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 228. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 229. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 230. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 231. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 232. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 233. GERMANY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 234. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 235. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 236. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 237. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 238. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 239. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 240. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 241. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 242. INDIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 243. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 244. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 245. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 246. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 247. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 248. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 249. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 250. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 251. BRAZIL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 252. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 253. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 254. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 255. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 256. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 257. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 258. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 259. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 260. MEXICO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 264. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 265. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 266. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 267. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 268. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 269. UNITED KINGDOM PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 270. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 272. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 273. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 274. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 275. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 276. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 277. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 278. FRANCE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 279. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 281. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 282. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE & PREVENTIVE CARE, 2017-2032 (USD MILLION)
TABLE 283. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 284. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 285. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSING PATTERN, 2017-2032 (USD MILLION)
TABLE 286. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 287. AUSTRALIA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 288. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 289. ITALY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2017-2032 (USD MILLION)
TABLE 29

Companies Mentioned

  • AstraZeneca PLC
  • Alnylam Pharmaceuticals, Inc.
  • Samsung Bioepis Co., Ltd.
  • Novo Nordisk A/S
  • Apellis Pharmaceuticals, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Akari Therapeutics, Plc
  • Amgen Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Kira Pharmaceuticals, Inc.
  • NovelMed Therapeutics, Inc.
  • Sanofi S.A.
  • Swedish Orphan Biovitrum AB

Table Information

Report AttributeDetails
No. of Pages184
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.88 Billion
Forecasted Market Value ( USD ) by 2032 $ 10.07 Billion
Compound Annual Growth Rate9.3%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report

  • Report
  • 126 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Report 2026 - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Share & Trends Analysis Report by Action of Mechanism, Route of Administration, End Use, Region, and Growth Forecasts, 2026-2033 - Product Image

Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Share & Trends Analysis Report by Action of Mechanism, Route of Administration, End Use, Region, and Growth Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Japan
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) Market Report 2026 - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Crovalimab Sales Forecast and Market Size Analysis - 2034 - Product Image

Crovalimab Sales Forecast and Market Size Analysis - 2034

  • Report
  • 30 Pages
  • Global
From

About the Paroxysmal Nocturnal Hemoglobinuria Drug Market

The Paroxysmal Nocturnal Hemoglobinuria (PNH) drug market is a specialized segment within the broader category of hematological drugs, which encompasses medications for a wide range of blood disorders. PNH is a rare, life-threatening blood disease characterized by the destruction of red blood cells, leading to hemoglobin release in the urine, particularly noticeable at night or in the early morning. Treatments for PNH focus on reducing hemolysis, preventing thrombosis, and improving quality of life. Historically, the management of PNH involved supportive treatments such as blood transfusions and iron therapy; however, the advent of novel targeted therapies has transformed the therapeutic landscape. These innovative drugs inhibit the complement system, which plays a central role in the pathophysiology of PNH. The development and approval of these complement inhibitors have provided patients with the first disease-specific treatments, substantially improving clinical outcomes. Several companies have made their mark in the PNH drug market, with a strong focus on research and development for more effective and patient-friendly treatments. Leading players include Alexion Pharmaceuticals, Inc., which developed eculizumab, a monoclonal antibody that has been a cornerstone in PNH treatment. Other notable companies operating in the space are Apellis Pharmaceuticals, which has made strides with its complement inhibitor pegcetacoplan, and Novartis, exploring gene-therapy approaches to provide long-term relief for patients afflicted by the disorder. These companies, along with others engaged in the Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.